Treatment News : Boosting Dose of Norvir Doesn’t Affect Insulin

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 6, 2010

Boosting Dose of Norvir Doesn’t Affect Insulin

Norvir (ritonavir)—when given at the type of low doses used to boost blood levels of other protease inhibitors—does not affect how the body uses insulin, according to a study published online June 30 in the Journal of Acquired Immune Deficiency Syndromes.

Full-dose Norvir was once considered among the most potent of the available protease inhibitors. Unfortunately, when it is taken at 800 milligrams (mg) per day, as it was in the late 1990s, it causes significant side effects, such as lowering the body’s ability to use insulin properly. This condition, called insulin resistance, can ultimately lead to diabetes, which in turn can increase the risk of cardiovascular disease.

Fortunately, Norvir is no longer used at the original dose. Rather, most people take only 200 mg per day in order to boost the blood levels of other protease inhibitors. What has remained unknown, however, is whether this lower dose might affect insulin in ways similar to the higher dose.

The answer that question, Steven Taylor, MD, from the University of California at San Francisco, and his colleagues, tested the level of insulin resistance in HIV-negative volunteers after they took a single dose of 200 mg of Norvir, and compared this with people taking a placebo.

Taylor’s group found that people taking Norvir were no more likely to have changes in their insulin or blood sugar than people taking a placebo. “Consideration should be given to these findings when assessing the metabolic effects of antiretroviral regimens and advising patients,” the authors conclude.

Search: Norvir, ritonavir, Norvir-boosted, boost, dose, protease inhibitors, insulin, insulin resistance, glucose, Steven Taylor


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adorableone
    New York
    New York


    zeze42
    Bay Area - Peninsula
    California


    latinpozdallas
    Dallas
    Texas


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.